<DOC>
	<DOCNO>NCT00955630</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness intravitreal ranibizumab ( Lucentis ) patient fluid blood leakage eye due ocular histoplasmosis .</brief_summary>
	<brief_title>Intravitreal Ranibizumab Treatment Choroidal Neovascularization Ocular Histoplasmosis Syndrome</brief_title>
	<detailed_description>Patients evaluate monthly one year . Participants assign one two group : Group A receive 3 monthly injection ranibizumab follow need injection throughout remainder study Group B receive injection ranibizumab need basis throughout study You take part study : 1 . You pregnant intend become pregnant next 12 month nurse infant 2 . You age 18</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>age 18 active choroidal neovascularization secondary ocular histoplasmosis Visual acuity 20/25 20/400 pregnancy intent become pregnant within next 12 month nurse infant premenopausal woman use contraception prior treatment subfoveal thermal laser allergy sodium fluorescein simultaneous participation another investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Histoplasmosis</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>OHS</keyword>
</DOC>